Physician profile
George B Ingrish
NPI 1154344513
$20,701.31
in general payments reported to CMS, 2019-2025
33 companies · $2,512 in 2025
The $2,512 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $586 · 2021: $1,258 · 2022: $1,655 · 2023: $5,324 · 2024: $8,634 · 2025: $2,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,328 · Food and Beverage: $6,369 · Travel and Lodging: $2,034 · Education: $394 · Honoraria: $300 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,327.50 |
| Food and Beverage | $6,368.97 |
| Travel and Lodging | $2,034.17 |
| Education | $393.99 |
| Honoraria | $300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $9,961.32 | 2022-2024 | Sotyktu |
| Abbvie INC. | $2,522.48 | 2019-2025 | |
| Janssen Biotech, INC. | $2,399.16 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $1,254.46 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $695.17 | 2019-2025 | |
| Ucb, INC. | $412.00 | 2019-2024 | Bimzelx |
| Pfizer INC. | $392.04 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $331.96 | 2019-2025 | |
| Leo Pharma INC. | $330.34 | 2019-2025 | Adbry |
| Dermavant Sciences, INC. | $317.74 | 2023-2024 | Vtama |
| Chiesi USA, INC. | $300.00 | 2025 | Filsuvez |
| Sun Pharmaceutical Industries INC. | $296.46 | 2019-2023 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $269.44 | 2024-2025 | Nemluvio, Aklief |
| Biofrontera INC. | $136.46 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Regeneron Healthcare Solutions, INC. | $134.72 | 2019-2025 | Libtayo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.64 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $109.19 | 2019-2021 | |
| Incyte Corporation | $84.35 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $83.82 | 2023-2025 | Zoryve |
| Amgen INC. | $75.78 | 2021-2024 | Otezla |
| Hill Dermaceuticals, INC. | $64.25 | 2023-2024 | Tolak |
| Vyne Pharmaceuticals INC. | $61.06 | 2020-2021 | |
| Kyowa Kirin, INC. | $60.91 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $54.32 | 2020-2021 | |
| Celgene Corporation | $47.26 | 2019 | |
| Almirall LLC | $44.96 | 2024 | Klisyri |
| Krystal Biotech INC | $30.74 | 2025 | Vyjuvek |
| Organon LLC | $25.27 | 2025 | Vtama |
| Botanix Sb INC | $19.88 | 2025 | Sofdra |
| Mallinckrodt Hospital Products INC. | $18.20 | 2024 | Acthar |
| Organogenesis INC. | $14.93 | 2023 | Puraply |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Epi Health, LLC | $6.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Ingrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.